Search for:
Search for:
Healthcare Professionals
Publications
Contact
News
Español
Magazine
Radio
*
INFÓRMESE
¿Qué es EM?
Un trastorno neurológico crónico que afecta el sistema nervioso central, compuesto por el cerebro...
Más detalles
MATERIALES EDUCATIVOS
PREGUNTAS COMUNES
Lending Library
Symptoms
Treatment Options
Additional Resources
INVESTIGACIÓN
MS Awareness Month
DONAR
OBTENGA AYUDA
Programa de Salud y Bi...
Obtenga materiales educativos y referencias así como también la oportunidad de participar en...
Más información
Grants & Programs
Awareness Campaigns
GRUPOS DE APOYO
Events
Lending Library
Additional Resources
PARTICIPE
Mes de Concientización...
Una campaña anual a nivel nacional con objetivos para promover la comprensión de la EM y ayudar a...
Más información
Advocacy
COMPRAS A SOCIOS
VOLUNTARIO
Businesses
MS Research Trials
Outreach
Supporter Program
Awareness Campaigns
Host an Event
Events
MS Focus on Fashion
The inaugural MS Focus on Fashion, will take place on Nov. 6, in Dania Beach, Fla.
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
QUIÉNES SOMOS
Programas y Subvenciones
Más detalles
Overview
Press Room
LIDERAZGO
Healthcare Advisory Board
ESTADOS FINANCIEROS
NUESTRA MISIÓN
Careers at MS Focus
Affiliations
PROGRAMA DE TECNOLOGÍA...
El Programa de Tecnología de Asistencia brinda información y financiamiento para dispositivos que...
/Get-Help/MSF-Programs-Grants/Assistive-Technology-Program
Shop
Privacy
Terms of Use
Site Map
Multiple sclerosis therapy improves gut flora
diciembre 02, 2022
A medication used to treat multiple sclerosis also has a beneficial effect on the composition of the intestinal flora, according to researchers. Conversely, the gut flora also plays a role in which side effects occur during treatment with the medication.
Few previous studies have examined the effects of MS treatments on intestinal flora and on the role their composition plays with regard to efficacy and side effects. A team of researchers at the University of Basel and the University Hospital Basel examined these questions in a group of 20 MS patients being treated with dimethyl fumarate.
The medication, which is sold under the brand name Tecfidera, reduces the number of MS flare-ups by interfering with the metabolic processes of certain immune cells. However, the therapy is also associated with side effects, including hot flashes and gastrointestinal complaints, and in some cases lymphopenia, a lack of lymphocytes such as B cells and T cells in the blood. This can lead to severe complications.
More “good” bacteria
In their study, the researchers examined stool and blood samples from participants before and during the first 12 months of the treatment. Their focus was on the composition of the gut microbiome. The research team also measured the number of lymphocytes in the blood in order to identify patients who were experiencing lymphopenia as a side effect.
After only three months of treatment, the research team was able to identify changes to the gut microbiome. They were able to show that the gut bacteria of patients receiving the medication started to become more like the composition seen in healthy individuals. Treatment with dimethyl fumarate reduced the proportion of proinflammatory types of bacteria, which have been linked to MS, and supported the growth of “good” bacteria.
Furthermore, the researchers were able to draw a connection between the composition of the gut microbiome and the development of lymphopenia: The presence of Akkermansia muciniphila bacteria combined with the lack of Prevotella copri bacteria emerged as a risk factor for this side effect. The authors therefore suspect that P. copri may protect against lymphopenia.
Interaction between therapy and gut flora
The data suggest that immunomodulatory therapies affect not only immune cells, but also positively influence the gut microbiome, the researchers said. The connection between gut bacteria and clinical side effects of the treatment may eventually enable early identification of patients at risk of developing lymphopenia. The researchers noted that in the future, this relatively new field of microbiology may help us better understand the effects and side effects of many medications with regard to gut bacteria, and to personalize treatment accordingly.
The researchers cautioned that this was only a pilot study with a relatively small number of participants. Larger-scale studies are needed to confirm the results and explore the potential for supporting MS therapies via gut flora and for predicting side effects in advance.
The findings were published in the journal
Gut Microbes
.
[Error loading the control 'FeaturedNews', check event log for more details]